Navigation Links
Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
Date:9/7/2011

60;Our next-generation URAT1 inhibitor, RDEA3170, is currently in Phase 1 clinical development. BAY 86-9766 (RDEA119) is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare. BAY 86-9766 (RDEA119) is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad, BAY 86-9766 (RDEA119), RDEA3170 and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
2. Ardea Biosciences to Present at Upcoming Investor Conferences
3. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
4. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
5. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
6. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
7. Ardea Biosciences Prices Public Offering of Common Stock
8. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
9. Ardea Biosciences to Present at Two Upcoming Investor Conferences
10. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
11. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Pittsburgh, PA (PRWEB) , ... August 28, 2015 ... ... Program Chairman, Chuck Gardner, has organized and will present a session on chemical ... September 2. This conference and exposition is Asia’s largest analytical and scientific instruments ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... Aug. 27, 2015 The National Necrotizing ... eyes—and life—were saved by doctors at Vanderbilt University Hospital ... NNFF, NovaBay Pharmaceuticals and Dr. John Crew , ... at Seton Medical Center in Daly City, ... a breakthrough approach, pioneered by Dr. Crew, that had ...
(Date:8/27/2015)... -- GlassesOff (OTCBB: GLSO), a visual neuroscience technology ... vision system, announced today a partnership with eight-time All-Star, ... to develop a new mobile app designed for professional ... on-court performance. Vision is the inception of every ... ball or blocking a pass. The critical impact vision speed ...
Breaking Biology Technology:U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... this series on e-discovery, we discussed the amendments to ... to address and resolve issues regarding the discovery of ... or a system of satisfying your obligation to preserve ... at risk. This article discusses how to minimize ...
... Madison, Wis. - NimbleGen Systems , a manufacturer ... toward an initial public offering of stock following its acquisition ... , ,NimbleGen had sought to raise $75 million in the ... by the two companies, Roche will acquire 100 percent of ...
... - In an effort to revive Legislative support for ... at Republican skeptics, suggesting that GOP lawmakers are paying lip ... farmers, manufacturers, and entrepreneurs. , ,Doyle, in his most pointed ... more than 100,000 tons of biomass resources and would benefit ...
Cached Biology Technology:Finding Safe Harbor in a sea of electronic discovery 2Finding Safe Harbor in a sea of electronic discovery 3NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 2NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 3NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 4
(Date:8/24/2015)... 2015 The consulting company Frost & ... manufacturer DERMALOG and its customized solutions and products for ... of the Year Award". DERMALOG is particularly successful with a ... -Cross reference: Picture is available at AP Images ... On Thursday evening, in South Africa,s ...
(Date:8/19/2015)... 2015  VOXX International Corporation (Nasdaq: VOXX ... a Definitive Agreement to purchase the assets, inclusive ... leader EyeLock through an acquiring entity.  Upon consummation ... interest in the acquiring entity. The closing of ... diligence.  Expanding on its existing supply chain and ...
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... worst enemy , Unlocking ancient rice secrets to overcome ... Reducing crop losses with cereals that respond to pest ... , Over 40 international research organisations are joining forces ... to improve food security in developing countries., Funding has ...
... culturally, and economically important plant in the Western United ... harvesters now have a comprehensive report about the species. ... Beargrass ( Xerophyllum tenax ), published by the U.S. ... gaps and areas for future research. It also documents ...
... with multiple sclerosis at the University of California, San Francisco ... exchange" that allows the disease-causing cells to move in and ... from spinal fluid and blood samples, are called B cells, ... but sometimes react strongly with the body itself. One of ...
Cached Biology News:Major international push to maximize bioscience research to help world's poorest farmers 2Major international push to maximize bioscience research to help world's poorest farmers 3Major international push to maximize bioscience research to help world's poorest farmers 4Beargrass, a plant of many roles, is focus of new report 2Multiple sclerosis 'immune exchange' between brain and blood is uncovered 2
Template and primers for preparation of internal control spots...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
...
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: